Circulating Carnosine Dipeptidase 1 Associates with Weight Loss and Poor Prognosis in Gastrointestinal Cancer

Cancer cachexia (CC) is linked to poor prognosis. Although the mechanisms promoting this condition are not known, several circulating proteins have been proposed to contribute. We analyzed the plasma proteome in cancer subjects in order to identify factors associated with cachexia. Plasma was obtain...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 10; no. 4; p. e0123566
Main Authors Arner, Peter, Henjes, Frauke, Schwenk, Jochen M., Darmanis, Spyros, Dahlman, Ingrid, Iresjö, Britt-Marie, Naredi, Peter, Agustsson, Thorhallur, Lundholm, Kent, Nilsson, Peter, Rydén, Mikael
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 21.04.2015
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0123566

Cover

More Information
Summary:Cancer cachexia (CC) is linked to poor prognosis. Although the mechanisms promoting this condition are not known, several circulating proteins have been proposed to contribute. We analyzed the plasma proteome in cancer subjects in order to identify factors associated with cachexia. Plasma was obtained from a screening cohort of 59 patients, newly diagnosed with suspected gastrointestinal cancer, with (n = 32) or without (n = 27) cachexia. Samples were subjected to proteomic profiling using 760 antibodies (targeting 698 individual proteins) from the Human Protein Atlas project. The main findings were validated in a cohort of 93 patients with verified and advanced pancreas cancer. Only six proteins displayed differential plasma levels in the screening cohort. Among these, Carnosine Dipeptidase 1 (CNDP1) was confirmed by sandwich immunoassay to be lower in CC (p = 0.008). In both cohorts, low CNDP1 levels were associated with markers of poor prognosis including weight loss, malnutrition, lipid breakdown, low circulating albumin/IGF1 levels and poor quality of life. Eleven of the subjects in the discovery cohort were finally diagnosed with non-malignant disease but omitting these subjects from the analyses did not have any major influence on the results. In gastrointestinal cancer, reduced plasma levels of CNDP1 associate with signs of catabolism and poor outcome. These results, together with recently published data demonstrating lower circulating CNDP1 in subjects with glioblastoma and metastatic prostate cancer, suggest that CNDP1 may constitute a marker of aggressive cancer and CC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: MR PA. Performed the experiments: TA BI P. Naredi KL FH JMS SD P. Nilsson MR. Analyzed the data: MR PA ID FH P. Nilsson BI KL. Contributed reagents/materials/analysis tools: MR PA KL FH P. Nilsson. Wrote the paper: MR PA KL BI P. Naredi PNi FH. Guarantor of the work: MR.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0123566